Collectively, these approaches offer an avenue for reducing radioresistance in PDAC while improving treatment response and minimizing normal tissue toxicity. Future research directions should include the incorporation of multi-omics data into predictive models for appropriate treatment selection, additional large-scale, biomarker-driven clinical trials, and continued integration of biomarker-targeting drug therapy, radiotherapy, and immunotherapy into treatment regimens.

1 day ago

Review • Journal • PARP Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1)

KRAS G12D • KRAS G12

Mapping metabolic reprogramming dynamics across pancreatic neuroendocrine tumor cell differentiation at single-cell transcriptomic resolution. (PubMed, Front Genet)

MALAT1, ATP5F1B, PKM, and NDUFS1 are positioned as key regulatory nodes. These findings refine current understanding of metabolic reprogramming during pNET differentiation and suggest targeting the OXPHOS-to-glycolysis transition as a potential therapeutic strategy in pancreatic neuroendocrine tumors.

1 day ago

Journal

FGFR1 (Fibroblast growth factor receptor 1) • KDR (Kinase insert domain receptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • SPP1 (Secreted Phosphoprotein 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • FGF2 (Fibroblast Growth Factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • ENO1 (Enolase 1) • ALDOA (Aldolase Fructose-Bisphosphate A) • NDUFS1 (NADH:Ubiquinone Oxidoreductase Core Subunit S1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. (PubMed, Cancer Treat Rev)

The substantial hereditary and potentially actionable molecular burden supports universal germline testing and comprehensive tumour genomic profiling, particularly in younger patients and in KRAS wild-type disease. PARP inhibitors should be described as improving progression-free survival or disease-control outcomes in selected BRCA-mutated metastatic PDAC rather than as having established a statistically significant overall survival benefit.

1 day ago

Clinical data • Review • Journal • BRCA Biomarker • PARP Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRCA (Breast cancer early onset)

KRAS wild-type • RAS wild-type • BRCA mutation

The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chemotherapy. (PubMed, BMC Cancer)

After 8 weeks of first-line chemotherapy, most patients with advanced PDAC were classified as SD and exhibited survival outcomes comparable to those with partial response. In patients with stable disease and elevated baseline CA19-9 levels, a ≥ 30% reduction in CA19-9 provided additional prognostic stratification.

1 day ago

Journal

CA 19-9 (Cancer antigen 19-9)

A novel EGR1-driven GLUL/mTOR axis regulates macropinocytosis-mediated crosstalk in pancreatic stellate cell-cancer metastasis. (PubMed, J Transl Med)

The EGR1-driven GLUL/mTOR axis in PSCs suppresses pancreatic cancer progression by inhibiting PSC activation, reducing cancer cell macropinocytosis, and restraining metastasis. This axis represents a promising therapeutic target for disrupting PSC-cancer cell crosstalk in pancreatic cancer.

1 day ago

Journal

EGR1 (Early Growth Response 1) • GLUL (Glutamate-Ammonia Ligase)

Gallbladder MiNEN arising in association with an intracholecystic papillary neoplasm exhibiting divergent p53 expression. (PubMed, Virchows Arch)

In line with previous reports, this case further suggests that ICPN may represent a common precursor lesion with the potential for divergent differentiation to GB MiNEN. The discordant p53 profiles observed across tumor components may be further explained by clonal evolution and intratumoral heterogeneity.

1 day ago

Journal

TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)

Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. (PubMed, J Gastroenterol)

Our findings reveal a novel TL1A-MAIT-CSF-1 axis that drives immunosuppression in PDAC by reprogramming innate immune responses. Targeting MAIT cells or TL1A signaling may represent a promising therapeutic strategy to improve immunotherapy efficacy in PDAC.

1 day ago

Journal

CSF1 (Colony stimulating factor 1)

SGNMesoC2-001: A Study of SGN-MesoC2 in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=19, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2028 --> May 2026; The trial was terminated for strategic reasons. The decision was not based on any safety concerns

1 day ago

Trial completion date • Trial termination • Trial primary completion date

Targeting the WASF3 Regulatory Complex in Pancreatic Cancer Using Stapled Peptides. (PubMed, Biochemistry)

Further, WAHM1 was found to permeate pancreatic cancer cell lines, bind to its protein targets in the WRC, and reduce WRC protein levels. WAHM1 may serve as a complementary strategy to downregulate WASF3-mediated migration and invasion in pancreatic cancer models.

1 day ago

Journal

WASF3 (WASP Family Member 3)

SIL204SL-P001: SIL204-SL Treatment for Locally Advanced Pancreatic Cancer (2025-525157-39-00)

P2/3, N=10, Not yet recruiting, Silexion Therapeutics Ltd.

1 day ago

New P2/3 trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation